Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADG126 Mono · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADG126 mono dose escalation | EXPERIMENTAL | ADG126 monotherapy dose escalation will be traditional 3+3 cohort design. |
| ADG126 mono dose expansion | EXPERIMENTAL | Monotherapy dose expansion is designed to evaluate the preliminary antitumor activity of ADG126 at RP2D or the doses approved by the SRC. |
| ADG126-anti PD1 drug dose escalation | EXPERIMENTAL | Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC. |
| ADG126-anti PD1 drug dose expansion | EXPERIMENTAL | Combination therapy expansion will commence at RP2D or the dose approved by the SRC. |
| ADG126-ADG106 dose escalation | EXPERIMENTAL | Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC. |
| ADG126-ADG106 dose expansion | EXPERIMENTAL | Combination therapy expansion will commence at RP2D or the dose approved by the SRC. |
| Name | Type | Description |
|---|---|---|
| ADG126 Mono | BIOLOGICAL | ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes. |
| ADG126-anti PD1 | BIOLOGICAL | ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion |
| ADG126-ADG106 | BIOLOGICAL | ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion |
Inclusion criteria 1. Adults ≥18 years of age. 2. ECOG performance status 0 or 1. 3. Estimated life expectancy of more than 12 weeks . 4. Patients with advanced or metastatic solid tumors, confirmed by histologically or pathologically documented, who have progressed after all standard therapies, or...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ADG126 Mono is an investigational monoclonal antibody being studied for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated as a monotherapy and in combination with other agents in patients with advanced solid tumors.
ADG126 Mono is being developed by Adagene Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ADAG. Adagene is conducting clinical trials to evaluate the safety and efficacy of ADG126 Mono in patients with advanced or metastatic solid tumors.
ADG126 Mono is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of advanced or metastatic solid tumors.
ADG126 Mono was studied in a Phase 1 clinical trial with the identifier NCT04645069. This trial evaluated ADG126 as a monotherapy, in combination with an anti-PD1 antibody, and in combination with ADG106 in patients with advanced or metastatic solid tumors. The trial enrolled 58 participants and was conducted in the United States, Australia, and Singapore.
ADG126 Mono refers to the use of ADG126 as a single agent, as opposed to its use in combination with other therapies. In clinical trials, ADG126 is studied both as a monotherapy and in combination with other drugs, such as an anti-PD1 antibody or ADG106.